Sulfaphenazole: Next-Generation CYP2C9 Inhibition and Antimycobacterial Research

Introduction

Sulfaphenazole has emerged as a pivotal research compound at the intersection of drug metabolism modulation and antibacterial innovation. As a selective inhibitor of cytochrome P450 enzymes CYP2C9 and CYP2C6, Sulfaphenazole is crucial for dissecting the complexities of drug-drug interactions and for driving forward the search for new strategies against Mycobacterium tuberculosis, including multidrug-resistant and extensively drug-resistant strains. This article provides a comprehensive, scientifically deep analysis of Sulfaphenazole’s mechanisms, utility, and recent optimization, distinguishing itself by focusing on how structure–activity insights and domain-bridging findings can elevate assay design and translational research.

Mechanism of Action of Sulfaphenazole

Sulfaphenazole (CAS No. 526-08-9) is a member of the sulfonamide class characterized by its selective and competitive inhibition of CYP2C9, a key isoform within the cytochrome P450 superfamily. By binding to the active site of CYP2C9, Sulfaphenazole effectively blocks the oxidative metabolism of numerous xenobiotics and endogenous substrates (source: product_spec). This mechanism underpins its widespread use in drug-drug interaction studies and pharmacogenetics, where precise modulation of metabolic activity is required.

Beyond its role in drug metabolism, Sulfaphenazole also acts as a competitive inhibitor of bacterial dihydropteroate synthase (DHPS), a key enzyme in the folic acid biosynthesis pathway. This dual functional profile enables it to disrupt bacterial proliferation, specifically in M. tuberculosis and other clinically relevant pathogens (source: paper).

Protocol Parameters

• CYP2C9 enzyme inhibition assay | 0.5–11.5 μM | In vitro CYP2C9/CYP2C6 inhibition | Matches reported IC₅₀ and supports sensitive kinetic studies | product_spec
• Anti-tuberculosis in vitro study | 5–30 μg/mL | Growth inhibition of M. tuberculosis (wild-type and XDR strains) | Delivers MICs comparable to published values; balances potency and cytotoxicity | paper
• Cell function assays | 1–10 μM | Endothelial/vascular function, oxidative stress, wound healing | Reflects concentrations effective in animal and cellular models | product_spec
• In vivo animal studies | 5.13 mg/kg, intraperitoneally, daily | Murine models of vascular dysfunction and wound healing | Demonstrated efficacy in improving vascular function and injury healing | product_spec
• Compound solubility | ≥13.15 mg/mL in DMSO, ≥9.92 mg/mL in EtOH (with sonication) | Stock preparation for in vitro/in vivo studies | Facilitates high-concentration dosing and compatibility with standard protocols | product_spec
• Recommended storage | -20°C | All research applications | Preserves compound integrity and assay reproducibility | workflow_recommendation

Reference Insight Extraction: Structure–Activity Optimization for Antimycobacterial Potency and Selectivity

While previous content has highlighted Sulfaphenazole's dual utility in drug metabolism and antibacterial research, few have dissected how recent structure–activity relationship (SAR) optimization has enhanced its potential as an antimycobacterial agent. The pivotal study by Chen et al. (paper) systematically modified the phenylpyrazole core of Sulfaphenazole, creating derivatives that preserved potent anti-M. tuberculosis activity while markedly reducing off-target CYP2C9 inhibition. This breakthrough demonstrates that the 4-aminobenzenesulfonamide moiety is essential for antibacterial action, and that rational modifications at specific ring positions can decouple antibacterial efficacy from unwanted metabolic inhibition.

Most notably, compound 10d achieved an MIC of 5.69 μg/mL against M. tuberculosis with a CYP2C9 IC₅₀ >10 μM, signaling a new path for designing agents with minimized drug-drug interaction risk. For researchers, this finding is transformative: it provides a blueprint for selecting or modifying sulfonamides to tailor activity profiles for specific assay or therapeutic needs—balancing efficacy, safety, and metabolic profile in a way not previously possible.

Comparative Analysis with Alternative Methods

Historically, CYP2C9 inhibition studies have relied on a handful of reference inhibitors—many of which lack the selectivity or safety profile required for advanced translational research. Sulfaphenazole distinguishes itself with a low IC₅₀ for CYP2C9 (0.63 μM) and minimal cytotoxicity (Vero cell IC₅₀ >64 μg/mL) (source: product_spec). When compared to other P450 inhibitors or sulfonamide antibiotics, Sulfaphenazole offers superior selectivity and a richer data set for both in vitro and in vivo applications. Its established pharmacologic profile permits confident extrapolation from bench to animal studies, a key advantage over less-characterized alternatives.

Additionally, Sulfaphenazole’s dual capacity as both a metabolic inhibitor and antibacterial agent is rarely matched by other single compounds. While related articles—such as “Sulfaphenazole: Bridging CYP2C9 Inhibition and Antitubercular Innovation”—have emphasized its dual function, this article extends the conversation by examining how recent SAR-driven innovations can inform the rational selection and customization of inhibitors for complex, multi-domain research strategies.

Advanced Applications: Vascular Function and Cross-Domain Research

Recent research has underscored the importance of CYP2C9-mediated oxidative stress in vascular endothelial dysfunction. By inhibiting CYP2C9, Sulfaphenazole restores endothelium-dependent vasodilation and reduces ischemia-reperfusion injury—effects validated in diabetic and injury models (source: product_spec). In preclinical studies, daily intraperitoneal dosing (5.13 mg/kg) improved vascular function and promoted wound healing by modulating inflammation, fibrosis, and macrophage activity.

Importantly, these vascular and tissue repair effects are mechanistically linked to Sulfaphenazole’s modulation of oxidative stress and metabolic byproducts—highlighting the compound as a bridge between metabolic, vascular, and infectious disease research. This cross-domain potential elevates Sulfaphenazole from a tool compound to a candidate for translational pipelines, particularly where drug-induced vascular toxicity or co-morbid infections are under investigation.

Why this cross-domain matters, maturity, and limitations

Bridging metabolic and infectious disease domains is not merely a theoretical exercise: in conditions such as diabetes or chronic wounds, altered drug metabolism and infection risk are deeply intertwined. Sulfaphenazole’s validated activity in both CYP2C9 inhibition and anti-M. tuberculosis assays enables integrated study designs that reflect real-world clinical complexity (source: paper). However, while animal model data are robust, the translation to human clinical protocols—particularly for combination therapies—remains a work in progress and should be approached with careful attention to interspecies differences (workflow_recommendation).

Intelligent Interlinking: Building on and Extending the Literature

While prior articles such as “Sulfaphenazole: Competitive CYP2C9 Inhibitor for Translational Research” have emphasized Sulfaphenazole’s selectivity and translational value, this piece diverges by focusing on how SAR-driven optimization can be strategically leveraged to minimize drug-drug interaction risks during antibacterial drug discovery. Additionally, whereas “Sulfaphenazole (SKU C4131): Data-Driven Solutions for CYP...” delivers practical protocol optimization and vendor selection guidance, our article synthesizes these workflow considerations with emerging scientific insights to empower users to make evidence-based decisions when customizing assay conditions or derivative compound selection. This deeper integration of SAR findings and protocol flexibility sets this article apart as a forward-looking resource for advanced investigators.

Practical Considerations for Laboratory Use

Successful deployment of Sulfaphenazole in research relies on precise handling and protocol design. The compound is insoluble in water but readily dissolves in DMSO (≥13.15 mg/mL) and ethanol (≥9.92 mg/mL with ultrasonication), supporting the preparation of concentrated stock solutions for both in vitro and in vivo studies (source: product_spec). Solutions are recommended for short-term use only, and all forms should be stored at –20°C to maintain stability.

Typical laboratory concentrations are 0.5–11.5 μM for CYP2C9 inhibition, 5–30 μg/mL for anti-tuberculosis assays, and 1–10 μM for cell-based or vascular function studies. These ranges are grounded in both product specifications and the latest peer-reviewed research, offering a robust foundation for experimental design (source: paper).

APExBIO’s Sulfaphenazole (SKU C4131) is widely regarded for its high purity and reliable performance, supporting sensitive and reproducible assay results.

Conclusion and Future Outlook

Sulfaphenazole stands at the forefront of next-generation research tools, uniquely positioned to support both the nuanced study of drug metabolism and the urgent search for new antimycobacterial agents. The latest SAR-driven optimizations, as detailed by Chen et al., provide actionable pathways for customizing compound profiles to minimize off-target effects while preserving or enhancing antibacterial potency (paper).

Looking ahead, Sulfaphenazole’s cross-domain applicability—from vascular research to infectious disease—offers a model for constructing more integrated and clinically relevant preclinical studies. However, further translational work is needed to bridge promising animal data to human protocols, particularly in complex, comorbid scenarios. Researchers are encouraged to leverage the compound’s flexibility, high safety margin, and the growing body of SAR knowledge to accelerate experimental innovation.

For advanced protocol guidance, validated reagents, and emerging best practices, consider APExBIO’s Sulfaphenazole as a foundation for robust, translationally relevant discoveries.